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SUMMARY
A 57-year-old Southeast Asian woman with a remote
history of adenoid cystic carcinoma (ACC) of the right
labium superius oris (upper lip) presented to the hospital
with vague epigastric pain. On workup, she was found to
have multiple pleural nodules. Histopathology confirmed
the diagnosis of metastatic ACC. After 8 months of active
surveillance, evidence of disease progression was found
and the patient was started on pembrolizumab. Follow-
up after starting pembrolizumab showed stable disease
with no significant side effects.

BACKGROUND

Adenoid cystic carcinoma (ACC) accounts for
approximately 10%–15% of all salivary gland
tumours and 1% of head and neck cancers.1 ACC
is generally characterised by its lengthy course,
indolent behaviour, delayed and silent metastasis.1
About 35%–50% of patients with this carcinoma
develop distant metastases, usually to the lungs
and less commonly to the liver and the bone.2 ACC
has a propensity for perineural invasion (PNI) and
extension beyond surgical margins.2 Pleural metastasis is extremely rare and has been reported only in
a few case reports.3 4 Despite being a slow-growing
tumour, ACC is associated with a high risk of
mortality and treatment is usually challenging.

CASE PRESENTATION

The patient is a 57-year-old Southeast Asian woman
with a history of ACC of the right labium superius oris (upper lip), status post surgical resection
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Figure 1 Chest X-ray showing a large left side pleural
effusion (arrow).

Figure 2 Positron emission tomography CT scan
showing a large left pleural effusion with numerous
hypermetabolic pleural-based nodules in the left
hemithorax consistent with malignancy (arrows).

followed by reconstruction and then adjuvant
radiation therapy 18 years ago in Singapore. The
patient moved to the USA in 2010 and presented to
the emergency department in August 2019 for evaluation of epigastric and left upper quadrant abdominal pain. The patient was in her usual state of good
health until 12 hours before presentation when she
started reporting of abdominal pain, nausea and
vomiting. A review of systems was significant for
intermittent dyspnoea on exertion. The patient vital
signs were stable. Physical examination was significant for decreased breath sounds at the left lung
base, with dullness to percussion. There was mild
tenderness on palpation of the epigastric region but
no guarding or rigidity.

INVESTIGATIONS

Laboratory studies showed haemoglobin 134 g/L,
white cell count 5.4×109/L, troponin 5 ng/mL, beta
natriuretic peptide 50 pg/mL and lipase 40 µg/L.
ECG revealed sinus rhythm with no ST-
segment
changes. Chest X-
ray revealed a large left side
pleural effusion (figure 1). Echocardiography
showed a normal ejection fraction of 55%–60%
with mild left ventricular hypertrophy. Ultrasound
of the abdomen was negative for cholecystitis
or pancreatitis. A CT of the abdomen revealed
numerous pleural-based lung nodules involving the
left lung, associated with a moderate to large left
pleural effusion. Due to the presence of pleural-
based lung nodules on CT scan and the patient’s
remote history of malignancy, a positron emission
tomography (PET) scan was ordered. This revealed
a large left pleural effusion with numerous hypermetabolic pleural-
based nodules (maximum standardised fluorodeoxyglucose (FDG) uptake value
7) in the left hemithorax consistent with malignancy (figure 2). A therapeutic and diagnostic
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Figure 4 (A) Pre-treatment CT of the chest o inFebruary 2020
showing progression of the left lung pleural-based nodules with the
largest measuring 10×6 mm in dimension. (B) Repeat chest CT in June
2020 after pembrolizumab showing stable disease (arrows).

Figure 3 Pathology with microscopy showing infiltrating epithelioid
neoplasm composed of columnar and cuboidal cells suggestive of large
cell carcinoma (arrows).
thoracentesis of the left pleural effusion was negative for malignancy by cytological analysis. Due to the unclear aetiology of
the pleural effusion, a video-assisted thoracoscopic surgery with
biopsy of the pleural nodules, talc pleurodesis and placement of
a pleural drainage catheter (PleurX) were done.
Biopsy showed an infiltrating epithelioid neoplasm composed
of columnar and cuboidal cells consistent with metastatic large
cell carcinoma (figure 3). Immunohistochemistry (IHC) staining
demonstrated scattered immunoreactivity for pan-
cytokeratin
AE1/AE3 and CAM 5.2 with a rare cell demonstrating immunoreactivity for CK7. Diffuse strong immunoreactivity was noted
for CK5/6, CD-117 and P63 with lesser immunoreactivity noted
for p53. The neoplastic cells did not demonstrate immunoreactivity for keratin 20 (CK20), epithelial membrane antigen
(EMA), thyroid transcription factor (TTF1) or calretinin, and the
Ki-67 proliferation rate was >10%. Based on the presence of the
Cytokeratin 7 (CK-7), anti-cytokeratin (CAM 5.2), CD117, p63
and pan-cytokeratin, this IHC staining pattern was suggestive of
ACC. Cytogenetics and next-generation molecular sequencing
of the tumour cells revealed chromosomal rearrangement for
myelobastosis viral oncogene homolog (MYB) and nuclear factor
I/B (NFIB) (MYB-NFIB) and also copy number gain of mouse-
double-minute 4 (MDM4). Microsatellite instability status was
high (MSI-H), and programmed death-ligand 1 receptor status
was negative.

DIFFERENTIAL DIAGNOSIS

Our initial differential diagnosis for this patient presenting with
epigastric and abdominal pain included cholecystitis, pancreatitis
and myocardial infarction. These diagnoses were excluded based
on the workup mentioned above. The presence of pleural effusion on CXR suggested the diagnosis of heart failure; however,
it was ruled out when Brain natriuretic peptide (BNP) and echocardiogram were normal. The presence of pleural-based lung
nodules on CT scan, in addition to the patient’s remote history
of malignancy, led us to believe that this could be a neoplastic
process; hence the PET scan was ordered and again showed
only the pleural nodules without any other lesions. At that
point, our differential diagnosis was primary pleural malignancy
versus metastasis of unknown origin. After taking biopsies of the
nodules and pathological evaluation, the final diagnosis of metastatic ACC was made.

TREATMENT

The case was reviewed at our multidisciplinary tumour board,
and given that the patient was asymptomatic, the consensus
2

decision was active surveillance with periodic clinical evaluations and serial CT imaging to be done every 3–6 months. CT
scans at 3 and 6 months showed stable disease.

OUTCOME AND FOLLOW-UP

On the eighth month of follow-up, the patient developed worsening abdominal pain. A CT scan of the chest, abdomen and
pelvis showed progression of the left pleural disease and a new
right lung nodule (figure 4A). After a discussion with the family,
and due to the progression of her disease, we decided to start
treatment with pembrolizumab 200 mg intravenously every
3 weeks.
The patient received three treatments so far with her most
recent imaging study (CT scan of the chest) at 2 and 4 months
of follow-
up showed stable appearance of the lung nodules
(figure 4B). Clinically, she is doing well only with intermittent
left-sided lower rib pain.
Case timeline appears in table 1.

DISCUSSION

ACC comprises around 10%–15% of salivary gland tumours and
approximately 1% of oral and maxillofacial tumours.1 The usual
primary site of ACC is in the parotid glands; other less common
sites include secretory glands in the trachea, the lacrimal glands
and the external auditory canal.1 ACC is generally characterised
by its lengthy course, indolent behaviour with delayed and silent
metastasis.1 ACC is similar to other head and neck cancers in
that it has a propensity to PNI and extension beyond surgical
margins.2 The most common clinical presentation of ACC is an
asymptomatic slowly growing mass in the head and neck, while
pain and paresthesia may reflect PNI.
Distant metastasis of ACC is more frequent than locoregional spread with an incidence of approximately 35%–50%.2
van Weert et al described 105 patients with ACC, of which 44
developed distant metastasis.5 The lungs were the most common
site of distant metastasis in 93%, followed by the liver and the
bones.5 Metastatic ACC to the pleural cavity with an isolated
pleural effusion is exceedingly rare, and to the best of our knowledge it has been described in only two case reports.3 4
The majority of metastatic disease in ACC develops within
5 years of diagnosis.5 The mechanism for the spread of ACC
is believed to be related to positive tumour margins, PNI, the
presence of nodal disease and advanced local disease.5 6 Van
Weert et al also reported that distant metastasis occurred in
some cases despite reasonable locoregional control, suggesting
unapparent micrometastasis at the time of surgical intervention.5
Patients with lung metastasis have been found to have a more
extended survival period compared with those with liver or bone
metastasis.1
MYB translocations are the most frequent mutations found
on chromosomal analysis of ACC.7 The translocation t(6;9)
Mosalem O, et al. BMJ Case Rep 2021;11:e237622. doi:10.1136/bcr-2020-237622
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Table 1

Case timeline

2002

Underwent surgical resection followed by reconstruction and then adjuvant radiation therapy of adenoid cystic carcinoma (ACC) of the right labium
superius oris (upper lip)

August 2019

Presented with vague epigastric pain and was found to have a large left pleural effusion with numerous hypermetabolic pleural-based nodules.
Underwent video-assisted thoracoscopic surgery with biopsy of the pleural nodules, talc pleurodesis and placement of a pleural drainage catheter
(PleurX). Biopsy consistent with metastatic ACC.

September 2019–February Active surveillance with periodic clinical evaluations and serial imaging done every 3–6 months that showed stable disease.
2020
February 2020

CT of the chest showed progression of the left pleural disease and a new right lung nodule.

March 2020

Treatment with pembrolizumab 200 mg every 3 weeks.

June 2020– till present

Repeat CT of the chest showed resolution of the right lung nodule and interval decrease in the size of the left pleural-based nodules.

(q22-23;p23-24) that results in a fusion of the two transcription
factor genes MYB and NFIB is detectable in half of the ACC’s
cases.7 The biological significance of MYB overexpression is an
upregulation of many target genes, including vascular endothelial growth factor (VEGF) A, fibroblast growth factor receptor
2 and KIT compared with normal salivary glands.8 Unlike other
head and neck cancers where tumour suppressor p53 mutations
are frequent, it has been identified only in approximately 5%
of ACC cases.6 9 Biomarkers, such as VEGF, p53 and KIT, have
been associated with aggressive disease and poor prognosis.1
Moreover, alterations of NOTCH signalling pathways have also
been found to be associated with an unfavourable prognosis.7
Our patient had the MYB-NFIB mutation as well as copy number
gain of MDM4.
Metastatic ACC is usually incurable, and treatment is mostly
directed towards palliation.10 Due to the lack of effective treatment options for metastatic disease, active surveillance of the
disease is recommended in asymptomatic patients with a slow
rate of metastatic tumour progression.11 12 Palliative chemotherapy for metastatic ACC can be given in the event of disease
progression or the presence of physical symptoms.10 A combination of cyclophosphamide, doxorubicin and cisplatin is the
most commonly studied regimen with a response rate of up to
50%; however, this regimen is highly toxic.12 For subsequent
lines of treatment, targeted therapy may be considered. Lenvatinib, a VEGF tyrosine kinase inhibitor, is a promising treatment
option for recurrent or metastatic ACC.8 In a single-arm study of
33 patients with recurrent ACC, lenvatinib resulted in a partial
response in 16% and stable disease in 75% of the patients.8
Initially, our patient underwent pleurodesis, and she was
asymptomatic following the procedure. Therefore, we decided
to observe her disease with serial CT scans. After evidence of
disease progression and recurrence of symptoms, we started her
on treatment with the immune checkpoint inhibitor pembrolizumab. Her tumour was MSI-H, and thereby, she was a candidate for treatment with pembrolizumab.
Pembrolizumab is a programmed cell death-
ligand (PD-
L1) monoclonal antibody that reverses T-cell suppression and
induces an antitumour response.13 Pembrolizumab was recently
approved for the treatment of unresectable or metastatic solid
tumours with MSI-H expression regardless of the histology of
the tumour or the tumour site.13 To the best of our knowledge,
pembrolizumab has not been previously reported as a treatment
for ACC.
Our patient received three treatments so far with pembrolizumab and her most recent CT imaging studies at 2 and 4 months
of follow-up showed stable appearance of the size of the pleural-
based nodules. Clinically, she is doing well only with intermittent
left-sided lower rib pain.
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Learning points
►► Adenoid cystic carcinoma is an indolent malignancy, and

metastatic disease can present many years following the
management of the primary tumour.
►► Chromosomal analysis and examining for microsatellite
instability are essential because they help to guide
management on the progression of the disease.
►► Pembrolizumab, a programmed death-ligand 1 checkpoint
inhibitor, can be offered to patients with high microsatellite
instability tumours regardless of tumour histology or origin.
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